What is the best medication to improve sleep continuity in a patient who frequently awakens during the night?

Best Medication for Frequent Nighttime Awakenings

For patients who wake up frequently during the night (sleep maintenance insomnia), low-dose doxepin (3-6 mg) is the best first-line pharmacological option, with nonbenzodiazepine BZRAs (particularly eszopiclone or extended-release zolpidem) as reasonable alternatives when doxepin is unavailable or not tolerated.

Treatment Algorithm

First Priority: Non-Pharmacologic Treatment

Before any medication, cognitive behavioral therapy for insomnia (CBT-I) should be attempted, as it demonstrates superior long-term outcomes compared to all pharmacologic options 1. However, when CBT-I is unavailable or the patient is unwilling/unable to pursue it, proceed to pharmacotherapy.

Medication Selection Based on Sleep Pattern

For sleep maintenance problems (frequent nighttime awakenings):

• First choice: Low-dose doxepin 3-6 mg

  • Specifically improves total sleep time, sleep quality, and wake after sleep onset 1
  • Demonstrated efficacy in both older and younger adults 1
  • No significant difference in adverse events compared to placebo in RCTs 1
  • Can be used longer-term with better safety profile than other options 1
  • Caveat: Unknown risk of suicidal ideation cannot be excluded, though no black box warning exists 1

• Second choice: Nonbenzodiazepine BZRAs

  • Eszopiclone or extended-release zolpidem specifically target sleep maintenance 1, 2
  • Improve wake after sleep onset, total sleep time, and sleep efficiency 1
  • Critical FDA warning: Risk of serious injuries from complex sleep behaviors (sleepwalking, sleep driving) 1
  • Must use lowest effective dose for shortest duration 1
  • Counsel all patients on these risks before prescribing 1

• Emerging option: Dual orexin receptor antagonists (daridorexant, suvorexant)

  • Specifically reduce the number and duration of long wake bouts (>6 minutes) throughout the night 3
  • Improvements in long wake bouts correlate with better daytime functioning 3
  • May be considered for up to 3 months 4
  • Newer agents with potentially favorable safety profile 5

Medications to AVOID

Do NOT use the following for sleep maintenance insomnia:

• Benzodiazepines: Despite improving sleep parameters, harms substantially outweigh benefits—risk of dependency, falls, cognitive impairment in elderly, respiratory depression, and diversion 1

• Trazodone: No difference in sleep efficiency or wake after sleep onset versus placebo; adverse effects outweigh limited benefits 1

• Antihistamines: Tolerance develops after 3-4 days; strong recommendation against use in older adults per 2019 Beers Criteria due to antimuscarinic effects 1

• Antipsychotics (quetiapine): Sparse evidence, serious harms including increased mortality in elderly with dementia 1

Practical Prescribing Strategy

Dosing approach:

• Start with lowest effective dose
• Consider non-nightly use (3-5 nights per week) to reduce tolerance and dependence risk 6, 4
• Limit initial prescription to 4 weeks, then reassess 1

Key monitoring points:

• Set clear expectations about short-term use at initiation 5
• Reassess after 4 weeks for efficacy and adverse effects
• Watch for next-day impairment, complex sleep behaviors, or tolerance
• Avoid dose escalation—if ineffective at standard dose, switch agents rather than increase 6

Critical Safety Considerations

For nonbenzodiazepine BZRAs specifically:

• Increased risk of fractures (adjusted OR 1.72) 7
• Risk of major head injury or fracture requiring hospitalization (adjusted HR 1.67) 7
• Memory and driving impairment documented in FDA medical reviews 7
• Some observational data suggest possible cancer and mortality associations, though inconsistent 7

For all hypnotics:

• Lack of long-term safety data beyond brief treatment periods raises concerns about extended use 1
• Benefits of short-term pharmacotherapy are consistently outweighed by CBT-I in long-term outcomes 1